SALES OF GENENTECH/ROCHE/CHUGAI'S HERCEPTIN FOR THE TREATMENT OF BREAST CANCER WILL NEARLY TRIPLE TO $3.3 BILLION

Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of Genentech/Roche/Chugai's Herceptin (trastuzumab) will nearly triple, reaching $3.3 billion in 2015, following positive data from several Phase III clinical trials that show improved disease-free survival of breast cancer patients.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-21-2006/0004384441&EDATE=)